| 证券代码：688026 | 证券简称：洁特生物 | 公告编号：2026-002 | | --- | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | | 1 | | 基金 | | | | --- | --- | --- | --- | | 9 10 | 中国银行股份有限公司－大成景恒混合型证券投资 李三喜 | 1,027,325 984,071 | 0.73 0.70 | 二、公司前十大无限售条件股东持股情况 | 序号 | 持有人名称 | 持股数量 | 占无限售条 件流通股的 | | --- | --- | --- | --- | | | | （股） | 比例（%） | | 1 | 袁建华 | 41,052,490 | 29.26 | | 2 | JET(H.K.) BIOSCIENCE CO., LIMITED | 17,547,293 | 12.51 | | 3 | 广州洁特生物过滤股份有限公司回购专用证券账户 | 2,730,914 | 1.95 | | 4 | 洛阳麦金顿企业管理合伙企业（有限合伙） | 2,387,938 | 1.70 | | 5 | 王少荣 | 2 ...

Core Viewpoint - The announcement details the conversion results and share changes related to the convertible bonds issued by Guangzhou Jet Biofiltration Co., Ltd, indicating minimal conversion activity since issuance. Group 1: Convertible Bond Issuance and Terms - The company issued 4.4 million convertible bonds with a face value of RMB 100 each, raising a total of RMB 44 million, with a maturity period from June 28, 2022, to June 27, 2028 [3] - The convertible bonds, named "Jet Convertible Bonds," began trading on the Shanghai Stock Exchange on August 2, 2022, under the code "118010" [3] - The conversion price was set at RMB 48.23 per share starting January 4, 2023 [3] Group 2: Conversion Status - As of December 31, 2025, a total of RMB 57,000 had been converted into 1,185 shares, representing 0.00084% of the total shares before conversion [2][5] - No bonds were converted between October 1, 2025, and December 31, 2025, with a total conversion amount of RMB 0.00 [2][5] - The remaining unconverted bonds amounted to RMB 439,943,000, which is 99.9870% of the total issuance [2][6] Group 3: Adjustments to Conversion Price - The conversion price was adjusted from RMB 48.23 to RMB 48.09 on June 6, 2023, due to the completion of the first vesting period of the 2021 restricted stock incentive plan [4] - Further adjustments to the conversion price are scheduled, with a decrease to RMB 48.02 on July 4, 2024, and to RMB 47.95 on July 2, 2025, as part of annual equity distribution plans [4]

| | | 转债代码：118010 转债简称：洁特转债 广州洁特生物过滤股份有限公司 可转债转股结果暨股份变动公告 ● 累计转股情况：截至 2025 年 12 月 31 日，"洁特转债"累计有人民币 57,000 元已转换为公司股票，转股数量为 1,185 股，占"洁特转债"转股前公司 已发行股份总额的 0.00084%。 ● 未转股可转债情况：截至 2025 年 12 月 31 日，"洁特转债"尚未转股的 可转债金额为人民币 439,943,000 元，占"洁特转债"发行总量的 99.9870%。 一、可转债发行上市情况 ● 本季度转股情况：公司向不特定对象发行可转换公司债券证券"洁特转 债"自 2023 年 1 月 4 日起可转换为公司股份。自 2025 年 10 月 1 日至 2025 年 12 月 31 日期间，"洁特转债"共有人民币 0.00 元已转换为公司股票，转股数量 为 0 股，占"洁特转债"转股前公司已发行股份总额的 0.00%。 经中国证券监督管理委员会《关于同意广州洁特生物过滤股份有限公司向不 特定对象发行可转换公司债券注册的批复》（证监许可〔2022〕432 号）同意注 册，广州洁特生 ...

Group 1 - The Shanghai Composite Index is at 4005.73 points, above the annual line, with an increase of 0.93% [1] - The total trading volume of A-shares today is 1,402.986 billion yuan [1] - A total of 154 A-shares have surpassed the annual line, with notable stocks showing significant deviation rates including Yingkang Life, Gangtong Medical, and Beilu Pharmaceutical at 10.63%, 10.61%, and 9.97% respectively [1] Group 2 - The top three stocks with the highest deviation rates from the annual line are: - Yingkang Life (12.85% increase, 10.63% deviation) - Gangtong Medical (11.91% increase, 10.61% deviation) - Beilu Pharmaceutical (10.20% increase, 9.97% deviation) [1] - Other notable stocks with significant increases include: - Guanhao Biological (14.87% increase, 8.29% deviation) - Baichu Electronics (6.95% increase, 6.79% deviation) [1] - Stocks with smaller deviation rates that have just crossed the annual line include *ST Yedao, Shiyan Institute, and Shanxi Securities [1]

Group 1 - Fenglong Co., Ltd. has no plans for restructuring or listing through the company in the next 36 months [1] - Wu Zhi Electromechanical's business in robotics and commercial aerospace accounts for approximately 1% of its main business revenue [1] Group 2 - Zhongse Co., Ltd.'s subsidiary plans to invest in a lead-zinc mining expansion project with a capacity of 1.65 million tons per year [1] - Tianyuan Co., Ltd.'s subsidiary intends to invest in a project to produce 100,000 tons of titanium dioxide via chlorination [1] Group 3 - Zhejiang Construction Investment's subsidiary signed a construction contract worth 1.8 billion yuan [1] - Jinpan Technology signed a contract worth approximately 696 million yuan for a data center project [1] - Shensi Electronics won a bid for the construction of low-altitude support facilities for the Jinan digital low-altitude flight management service platform [1] Group 4 - Yalake Co., Ltd. plans to acquire a 51% stake in Wukuang Salt Lake [1] - Shengxin Lithium Energy's subsidiary intends to acquire a 30% stake in Qicheng Mining [1] - Jiete Biological plans to acquire 70% of Jieke Membrane for 7.9199 million yuan [1] Group 5 - Baili Tianheng plans to repurchase shares worth 100 million to 200 million yuan [2] - Zhongju Gaoxin intends to repurchase shares worth 300 million to 600 million yuan [2] - Jiete Biological plans to repurchase shares worth 15 million to 30 million yuan [1][2] Group 6 - Zijin Mining expects a net profit increase of approximately 59% to 62% for the year 2025 [2] - Zongheng Co., Ltd. plans to raise no more than 548 million yuan through a private placement [2]

Group 1 - The company, JieTe Bio, announced the approval of several key resolutions during its 26th meeting of the fourth board of directors, including the acquisition of a 70% stake in Guangdong JieKe Membrane Separation Technology Co., Ltd. [2] - The company also approved a proposal to postpone certain fundraising investment projects [2] - Additionally, the company resolved to repurchase its shares through centralized bidding [2]

Group 1 - The company plans to repurchase shares through centralized bidding, with a total amount between 15 million and 30 million yuan, and a maximum repurchase price of 25.32 yuan per share, which is 58.75% higher than the current price of 15.95 yuan [1] - The company has seen a cumulative stock price increase of 24.87% this year [1] - The company specializes in the research, production, and sales of disposable plastic consumables for biological laboratories, with main business revenue composition being 60.24% from liquid handling, 30.74% from biological culture, and 4.98% from other sources [1] Group 2 - As of September 30, the number of shareholders increased by 5.43% to 8,274, while the average circulating shares per person decreased by 5.12% to 16,959 shares [2] - For the period from January to September 2025, the company achieved operating revenue of 398 million yuan, a year-on-year increase of 1.88%, and a net profit attributable to shareholders of 57.29 million yuan, a year-on-year increase of 14.22% [2] - The company has distributed a total of 152 million yuan in dividends since its A-share listing, with 30.06 million yuan distributed over the past three years [3]

| 证券代码：688026 | 证券简称：洁特生物 公告编号：2025-071 转债简称：洁特转债 | | --- | --- | | 转债代码：118010 | | 为规范公司募集资金管理和使用，保护投资者权益，经公司董事会批准，公 司设立了募集资金专项账户，募集资金到账后，已全部存放于募集资金专项账户 内。公司已与保荐机构、存放募集资金的商业银行签署了募集资金监管协议。 二、募集资金投资项目及使用情况 1 | 根据《广州洁特生物过滤股份有限公司向不特定对象发行可转换公司债券募 | | --- | | 集说明书》，公司本次募集资金总额扣除发行费用后将具体投资于以下项目： | | 序号 | 项目名称 | 投资总额（万元） | 拟使用募集资金 | | --- | --- | --- | --- | | | | | 额（万元） | | 1 | 生物实验室耗材产线升级智能制造项目 | 37,669.52 | 35,000.00 | | 2 | 生物实验室耗材新产品研发项目 | 4,014.23 | 4,000.00 | | 3 | 补充流动资金 | 5,000.00 | 5,000.00 | | | 合计 | 46 ...

重要内容提示： | 证券代码：688026 | 证券简称：洁特生物 | 公告编号：2025-070 | | --- | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | | 广州洁特生物过滤股份有限公司 关于收购部分股权暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 基于广州洁特生物过滤股份有限公司（以下简称"公司"）的整体发展规 划，公司拟向广州拓展投资管理有限公司（以下简称"拓展投资"）、袁建华、 Yuan Ye James、Dannie Yuan（以下合称"转让方"）合计收购广东洁科膜分离技 术有限公司（以下简称"洁科膜"或"标的公司"）70%股权，交易金额为人民币 7,919,870.00 元。本次交易完成后，公司将直接持有洁科膜 70%股权，洁科膜将 成为公司的控股子公司，纳入公司合并报表范围。 本次交易对手方包含公司控股股东袁建华及其一致行动人，本次交易构 成关联交易，但不构成《上市公司重大资产重组管理办法》规定的重大资产重组。 本次关联交易实施不存在重大法律障碍 ...

经中国证券监督管理委员会《关于同意广州洁特生物过滤股份有限公司向不 特定对象发行可转换公司债券注册的批复》（证监许可〔2022〕432 号）同意注 册，公司向不特定对象共计发行 440.00 万张可转债，每张面值为人民币 100 元， 按面值发行。本次发行的募集资金总额为 440,000,000.00 元，扣除承销及保荐费、 律师费、验资费、资信评级费和发行手续费等与发行可转换公司债券直接相关的 外部费用后，实际募集资金净额为 432,491,507.35 元。上述募集资金已全部到位， 并由天健会计师事务所（特殊普通合伙）于 2022 年 7 月 4 日对本次发行的资金 到账情况进行了审验，出具了《广州洁特生物过滤股份有限公司向不特定对象发 行可转换公司债券募集资金实收情况验证报告》（天健验〔2022〕7-67 号）。 为规范公司募集资金管理和使用，保护投资者权益，经公司董事会批准，公 司设立了募集资金专项账户，募集资金到账后，已全部存放于募集资金专项账户 内。公司已与保荐机构、存放募集资金的商业银行签署了募集资金监管协议。 关于广州洁特生物过滤股份有限公司 部分募集资金投资项目延期的核查意见 国联民生证券承 ...